Gene · 57674
RNF213: ring finger protein 213
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RNF213: ring finger protein 213. Genes, record 57674. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/57674
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q63HN8 | E3 ubiquitin-protein ligase RNF213 | 5,207 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents8
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 62280 | Q63HN8 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3751 | Q63HN8 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3751 | Q63HN8 | Espacenet |
| JP 2022141755 A | 2022-09-29 | 96 | Q63HN8 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 242715 | Q63HN8 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 242715 | Q63HN8 | Espacenet |
| JP 2016519285 A | 2016-06-30 | 96 | Q63HN8 | Espacenet |
| JP 2015516143 A | 2015-06-08 | 242715 | Q63HN8 | Espacenet |
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants651
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RNF213 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 3 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 3 | 2025 |
| R01NS110395 | Endolysosomal Proteome Landscapes Through the Lens of Neurodegenerative Risk Alleles | 3 | 2025 |
| R35GM142486 | Exploiting bacterial effector proteins to study human ubiquitin signaling | 3 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 2 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 2 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 2 | 2025 |
1 to 10 of 651Source NIH's project files
See all 651 nih grantsPapers1,364
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and genotype-phenotype correlation of RNF213 p.R4810K and non- p.R4810K variants in Moyamoya disease in an Indian cohort. | Front Neurol | 2026 | 42824198 | PubTator, text mining | PubMed |
| ZNFX1, an immunoregulatory RNA helicase and E3 ubiquitin ligase, assembles into pleiomorphic polymers. | Mol Cell | 2026 | 42822417 | PubTator, text mining | PubMed |
| Toxoplasma gondii GRA66 prevents premature egress driven by the host phospholipase RARRES3, independently of RNF213. | bioRxiv | 2026 | 42818749 | PubTator, text mining | PubMed |
| RNF213 regulates palmitate signaling through AAA+ and RZ-finger domains, a process enhanced by gain-of-function moyamoya disease-associated mutations. | FEBS J | 2026 | 42681960 | PubTator, text mining | PubMed |
| Plasma signatures of type 2 inflammation and vascular remodeling in moyamoya disease. | J Neurol Sci | 2026 | 42664850 | PubTator, text mining | PubMed |
| RNF213-dependent lytic destruction of Chlamydia-containing vacuoles activates host cell death pathways. | Proc Natl Acad Sci U S A | 2026 | 42658761 | PubTator, text mining | PubMed |
| Pulmonary Arterial Hypertension With Moyamoya Disease Harboring the RNF213 p.Arg4810Lys Variant Presenting a Favorable Response to Monotherapy: A Case Report. | Pulm Circ | 2026 | 42657248 | PubTator, text mining | PubMed |
| RNF213 in Panvascular Disease: A Molecular Hub Linking Genetic Susceptibility to Systemic Vasculopathy. | Biomedicines | 2026 | 42652131 | PubTator, text mining | PubMed |
| Independent Association of RNF213 p.R4810K With Extracranial Carotid Artery Disease Beyond Intracranial Atherosclerosis. | Stroke | 2026 | 42644243 | PubTator, text mining | PubMed |
| Pediatric moyamoya: current evidence and updates in evaluation and management. | Curr Opin Pediatr | 2026 | 42627237 | PubTator, text mining | PubMed |
1 to 10 of 1,364
See all 1,364 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/57674
GET https://conductscience.org/api/genes/v1/57674/grants?page=2